The Uttar Pradesh State Industrial Development Authority (UPSIDA) has signed a strategic Memorandum of Understanding (MoU) with the Jawaharlal Nehru Port Authority (JNPA) to position the upcoming Lalitpur Pharma Park as a major global pharmaceutical export hub. The pact will integrate the park with dedicated freight corridors and JNPA’s maritime network for faster, cost effective movement of raw materials and finished pharma products.
Glimpse:
The Lalitpur Pharma Park spans nearly 1,470 acres and is projected to attract investments exceeding ₹12,000 crore. The collaboration will link the park to the Western and Eastern Dedicated Freight Corridors via the Dadri-Khurja rail link, enabling seamless multimodal connectivity to JNPA India’s largest container port, which handles nearly half of the country’s containerised cargo and connects to over 200 global ports. The MoU was signed by UPSIDA CEO Vijay Kiran Anand and JNPA Chairman Gaurav Dayal.
In a significant boost to Uttar Pradesh’s pharmaceutical ambitions, UPSIDA and the Jawaharlal Nehru Port Authority have entered into a strategic partnership to develop the Lalitpur Pharma Park as a world class export gateway. The MoU aims to create robust logistics infrastructure that connects northern India’s pharma manufacturing ecosystem directly to international markets through efficient rail and sea routes.
India’s pharmaceutical industry, often called the “pharmacy of the world,” currently exports medicines to over 200 countries and is valued at around USD 50 billion. The Lalitpur Pharma Park, spread across nearly 1,470 acres, is expected to attract investments of more than ₹12,000 crore and generate substantial employment opportunities. The new agreement will ensure seamless movement of high value pharmaceutical goods by integrating the park with the Western Dedicated Freight Corridor (WDFC), Eastern Dedicated Freight Corridor (EDFC), and the Dadri Khurja rail link, ultimately linking it to JNPA India’s busiest container port.
This multimodal connectivity will significantly reduce transit times, lower logistics costs, and improve export reliability for both imports of raw materials and exports of finished drugs, APIs, generics, and vaccines. The partnership will also foster better coordination among industry players, logistics providers, and government agencies to build a responsive supply chain tailored to the complex needs of the pharmaceutical sector.
The initiative is expected to strengthen India’s position in the global pharma supply chain and support long term export growth amid rising international demand.
“By partnering with JNPA, we are enabling world-class logistics facilities for our investors. Integration with dedicated freight corridors will allow pharmaceutical manufacturers to access markets with unprecedented speed, significantly enhancing their global competitiveness.”
By
HB Team
